Clinical Trial to Evaluate the Safety and Tolerability of Hydrogen in Patients With Parkinson's Disease
Status:
Terminated
Trial end date:
2021-04-29
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled, double-blind trial that will investigate the safety and
tolerability of molecular hydrogen, a promising antioxidant agent, in patients with
early-stage Parkinson's Disease. The medication will be administered orally as 8 ounces of
hydrogen-enriched drinking water twice a day over the course of one year.